{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-004387","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.504387+00:00","generated_at":"2026-06-07T02:15:16.634199+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024","bullets":["Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.","Global pivotal program for ANX007 in geographic atrophy (ARCHER II) to initiate mid-2024 with vision preservation as primary endpoint","Proof-of-concept study for oral C1s inhibitor ANX1502 in cold agglutinin disease to start first half of 2024","Completed $125 million financing extends operating runway into second quarter 2026","ANX007 received PRIME designation in EU; to launch head-to-head ARROW trial vs. SYFOVRE in late 2024"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-004387","json":"https://secwatch.observer/filing/0001193125-24-004387.json","markdown":"https://secwatch.observer/filing/0001193125-24-004387.md","text":"https://secwatch.observer/filing/0001193125-24-004387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/0001193125-24-004387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524004387/d609684d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:15:16.634199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}